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Abstract 
Introduction: Cystic fibrosis (CF) is a life-limiting multisystemic genetic disease. Patients with CF have a high rate of hospitali-
zation. We attempt to ascertain national trends of inpatient stays, prevalence of various co-morbidities during hospitalizations, 
outcomes and discharge disposition among CF patients. 
Material and methods: Data from the National Inpatient Sample (NIS) was used to identify all hospitalizations of patients with 
CF and their demographic characteristics from 2003 to 2013. Prevalence and effects of various co-morbidities like acute kidney 
injury (AKI) were determined. Detailed sub-group analysis was performed for individuals with lung transplant. 
Results: The annual rate of hospitalization per 1,000 CF patients in the U.S. increased from 994 in 2003 to 1,072 in 2013. The 
overall in-hospital mortality was 1.5%; median age at death was 27 years. In-hospital mortality trended down from 1.9% to 1.2% 
from 2003 to 2013 (p-value for trend: 0.002). The median length of stay was 7 days. The prevalence of chronic liver disease and 
AKI was 3.7% and 3.8% respectively. Multivariate adjusted odds of mortality for AKI was 1.74 (95% CI 1.57−1.93, p < 0.001). 
Patients with prior lung transplantation accounted for 6.5% of hospitalizations. These patients had a significantly higher prevalence 
of AKI. 
Conclusions: The annual hospitalization rates of CF patients is increasing over the years. Females with CF constitute a higher 
proportion of hospitalized patients despite a higher male preponderance of males with CF in the community. AKI is associated with 
a significantly higher in-hospital mortality. Lung transplant recipients have a higher prevalence of AKI and mortality.
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Introduction
Cystic fibrosis (CF) is a life-limiting genetic 
disease involving multiple organ systems. About 
30,000 individuals are presently living with CF in 
the United States (U.S.) and 70,000 worldwide [1]. 
The most common organ systems involved are 
respiratory and gastrointestinal system. Patients 
with CF experience chronic airway infection with 
progressive deterioration in pulmonary function 
as well as episodic pulmonary exacerbations [2, 3]. 
They often require inpatient care during these 
pulmonary exacerbations [4]. Patients with CF 
also suffer from other serious conditions like 
acute pancreatitis and liver disease, which might 
warrant or complicate inpatient care [5]. As a re-
sult, patients with CF have a high rate of hospitali-
zation. The population prevalence of CF has been 
increasing despite fairly stable incidence due to 
longer survival as a  result of improved quality 
of care. Based on the data from CF Foundation 
Patient Registry (CFFPR), the number of people 
with CF in the U.S. increased from 21,488 in 2003 
to 28,134 in 2013 [1]. During the same period, 
the number of newly diagnosed individuals per 
year remained fairly stable (1,044 in 2003 and 
1,039 in 2013). 
The annual number of hospitalizations of 
individuals with CF is expected to increase with 
increasing prevalence. The factors affecting ove-
rall prognosis in CF are well defined, however, 
factors affecting in-hospital outcomes of patients 
with CF have not been studied in detail. Also, 
there is limited data on complications and outco-
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mes of hospitalized individuals with a prior lung 
transplant. In this study, we report the temporal 
national trends of hospitalizations of people with 
CF and their characteristics in the U.S. between 
2003 and 2013. We also identify the burden of co
-morbidities and complications among inpatients 
with CF and their impact on outcomes. Lastly, we 
examine the outcomes of hospitalized CF patients 
with a prior lung transplant. 
Material and methods
Data source
The National Inpatient Sample (NIS) pre-
viously known as Nationwide Inpatient Sample 
is one of the databases developed for the Heal-
thcare Cost and Utilization Project (HCUP) by 
the Agency of Healthcare Research and Quality 
(AHRQ) [6]. It is the largest inpatient database 
in the United States (U.S.) and has been used by 
researchers and policymakers to estimate heal-
thcare utilization and outcomes. Prior to 2012, 
the data was obtained from a sample of hospitals 
from which all discharge records were retained 
to approximate discharges from a 20% stratified 
sample of all U.S. hospitals. Beginning in 2012, 
NIS was redesigned to contain a sample of di-
scharges from all HCUP-participating hospitals 
across 44 states. NIS database now approximates 
20% stratified sample of all discharges from all 
U.S. hospitals. Sampling weights are provided 
to produce national-level estimates. After re-
designing the NIS, new sampling weights were 
created for trend analysis for the years before 
2012 to account for the new design. Every ho-
spitalization is de-identified and converted into 
one unique entry which provides demographic 
information (age, sex, race etc.), one primary and 
up to 24 secondary discharge diagnoses, length of 
stay, outcomes, and Elixhauser comorbidities [7]. 
The discharge diagnoses are provided in the 
form of International Classification of Diseases, 
9th Revision, Clinical Modification code (ICD-9-
CM). This study did not require review from the 
Institutional Review Board (IRB). 
Study population
Data from NIS between 2003 and 2013 was 
used to identify patients with CF (ICD-9-CM: 
277.00–277.09). Full description of ICD-9-CM 
codes used for the study is provided in Table 1. We 
excluded all cases with missing age and gender 
variables (0.3% of hospitalizations). Patients with 
prior lung transplant were identified by presence 
of codes for lung transplant (V42.6, 996.84) and 
lacking procedure codes of lung transplant sur-
gery in that hospitalization. Acute kidney injury 
(AKI) was identified with diagnosis codes 584.5 
to 584.9. Patients with AKI requiring dialysis 
(AKI-D) were identified using methods validated 
for use with administrative databases [8]. Other 
co-morbidities were identified by their respective 
ICD-9-CM codes as shown in Table 1. 
Statistical analysis 
Stata 13.1.0 (Stata Corp, College Station, 
TX) and SPSS 23.0 (SPSS Inc., Chicago, Ill) 
were used for all statistical analyses. Sampling 
weights provided by HCUP were used to produce 
national level estimates. Demographics, hospital 
characteristics, and outcomes of all cases with CF 
were obtained. Prevalence of various co-existing 
conditions and their mortality were calculated. 
c2 test of trend for proportions was used with 
the Cochrane Armitage test through the “ptrend” 
command in Stata to determine statistical si-
gnificance of trend for categorical variables [9]. 
Independent-Samples t-test and Chi-square test 
were used to determine statistical significance 
between groups. Multivariate logistic regression 
model was used to determine the adjusted impact 
of co-morbidities on in-hospital mortality. A 2 
sided p-value of less than 0.05 was considered 
statistically significant. 
Results
A  total of 311,651 hospitalizations of pa-
tients with CF were reported in the U.S between 
2003 and 2013. The number of hospitalizations 
per 1,000 CF patients in the U.S. increased from 
994 in 2003 to 1,072 in 2013. The demographic 
characteristics and outcomes of the patients are 
summarized in Table 2. The mean age of all the 
hospitalized CF patients in our study was 22.3 
years (SD = 13.4). The mean age of CF patients 
in community in the U.S. in 2013 was 20.2 [1]. 
This difference highlights the fact that older CF 
patients are hospitalized more often leading to 
a higher mean age of the hospitalized popula-
tion. More women with CF were hospitalized 
compared to men, overall, as well as during 
individual years. Almost two-thirds of hospi-
talized CF patients were adults ≥ 18 years of 
age). Overall, the median age at death was 27 
years and in-hospital mortality was 1.5%. The 
mortality among adults was 2% compared to 
0.6% among individuals less than 18 years of 
age. There was no gender difference in mortality 
(1.5% in each group). 
Advances in Respiratory Medicine 2016, vol. 84, no. 6, pages 316–323 
318 www.journals.viamedica.pl
Table 1. List of ICD-9-CM codes used in the study
Cystic fibrosis
Cystic fibrosis without mention of meconium 
ileus
277.00
Cystic fibrosis with meconium ileus 277.01
Cystic fibrosis with pulmonary manifestations 277.02
Cystic fibrosis with gastrointestinal  
manifestations
277.03
Cystic fibrosis with other manifestations 277.09
Chronic non-alcoholic liver disease
Cirrhosis of liver without mention of alcohol 571.5
Biliary cirrhosis 571.6
Other chronic nonalcoholic liver disease 571.8
Unspecified chronic liver disease without 
mention of alcohol
571.9
Acute pancreatitis 577.0
Lung transplantation
Lung transplant status V42.6
Complications of transplanted lung 996.84
Acute kidney injury
Acute kidney failure with lesion of tubular 
necrosis
584.5
Acute kidney failure with lesion of renal  
cortical necrosis
584.6
Acute kidney failure with lesion of renal  
medullary [papillary] necrosis
584.7
Acute kidney failure with other specified  
pathological lesion in kidney
584.8
Acute kidney failure, unspecified 584.9
Dialysis
Renal dialysis status V45.11
Encounter for extracorporeal dialysis V56.0
Fitting and adjustment of extracorporeal 
dialysis catheter
V56.1
Hemodialysis 39.95
The in-hospital mortality trended down from 
1.9% in 2003 to 1.2% in 2013 (p-value for trend: 
0.002) (Fig. 1). The median length of stay was 
7 days (Interquartile range [IQR] = 10 days) which 
remained fairly constant from 2003 through 2013. 
Table 3 provides information on hospital cha-
racteristics, insurance, and discharge disposition 
for these patients. The majority of hospitaliza-
tions occurred in large sized teaching hospitals 
located in urban areas. About 21% of patients 
were discharged with home health care, whereas, 
only about 3% required discharge to short or long 
term care facilities (including skilled nursing 
facility, intermediate care facility, and long term 
care hospital etc.).
Co-existing conditions 
Table 4 reports the prevalence of AKI, acute 
pancreatitis, and chronic non-alcoholic liver dise-
ase among the hospitalized CF patients. AKI was 
reported in 11,792 (3.8%) hospitalizations of CF 
patients. These patients were significantly older 
than those without AKI [32.1 ± 13.8) vs 21.9 ± 13.2) 
years, p < 0.001). 9.3% of cases with AKI required 
dialysis (AKI-D). A multivariate regression model 
was created to analyze the effect of AKI on in-ho-
spital mortality. Covariates for the model included 
demographics (age, gender, race); all Elixhauser 
co-morbidities (excluding renal failure), hospital 
characteristics (teaching status, location, bed-size), 
and need for mechanical ventilation. After adjusting 
for these variables, the odds of in-hospital mortality 
with AKI was 1.74 (95% CI 1.57−1.93, p < 0.001). 
Underlying chronic liver disease was recor-
ded in 3.7% of hospitalized CF patients. Acute 
pancreatitis was present in 1.7% of cases. Figure 2 
demonstrates the distribution of hospitalizations 
by each calendar month. 
Lung transplant recipients
Individuals with prior lung transplant con-
stituted 20,112 (6.5%) of all hospitalizations of 
patients with CF. These patients were significantly 
older compared to patients without transplant 
[30.5 (± 11.0) years vs 21.8 (± 13.4) years, 
p < 0.001). Table 5 provides the demographics, 
co-morbidities, primary discharge diagnosis, and 
outcomes of these patients. About 40% of these 
hospitalizations were related to complications 
of transplanted lungs. AKI occurred in 19.7% of 
transplanted patients compared to 2.7% without 
a  transplant (p < 0.001). 11.2% of transplant 
patients with AKI required dialysis. Figure 1 
provides a graphical display of temporal trend of 
mortality among individuals with lung transplant. 
DISCUSSION
This study reports the data of hospitaliza-
tions of CF patients using a  large, nationally 
representative sample of the U.S. population. 
The results indicate that annual number of hospi-
talizations of patients with CF is increasing over 
the last decade which is in part due to the rising 
prevalence of CF in the U.S. Even after adjusting 
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Table 2. Clinical characteristics and outcomes of hospitalized patients with cystic fibrosis from 2003 through 2013
Year 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Overall
Observations, N 21,355 23,354 33,113 24,700 25,262 32,173 25,117 33,642 33,175 29,605 30,155 311,651
Mean age
(SD), years
20.9 
(12.7)
20.9 
(13.1)
19.9 
(12.4)
21.7 
(13.2)
22.3 
(13.4)
23.2 
(13.2)
23.5 
(13.8)
21.8 
(13.3)
24.0 
(13.5)
23.1 
(13.9)
23.6 
(14.1)
22.3
(13.4)
Distribution  
by age, %
Age ≥ 18 years 59.3 59.3 54.8 61.1 63.5 67.3 69.1 61.2 69.9 65.6 66.8 63.6
Age < 18 years 40.7 40.7 45.2 38.9 36.5 32.7 30.9 38.8 30.1 34.4 33.2 36.4
Gender, %
Male 46.9 47.4 47.9 44.6 44.8 44.4 46.6 44.9 45.3 46.3 45.3 45.8
Female 53.1 52.6 52.1 55.4 55.2 55.6 53.4 55.1 54.7 53.7 54.7 54.2
In-hospital 
mortality, %
1.9 1.5 1.4 1.4 1.6 1.7 1.5 1.4 1.6 1.5 1.2 1.5
Mortality  
(by gender), %
Male 1.9 1.5 1.3 1.3 1.7 1.9 1.5 1.4 1.6 1.3 1.4 1.5
Female 1.8 1.5 1.5 1.5 1.4 1.6 1.6 1.5 1.6 1.6 1.1 1.5
Mortality 
(by age), %
Age < 18 0.7 0.5 0.7 0.7 0.7 0.5 0.5 0.5 0.6 0.8 0.5 0.6
Age ≥ 18 2.7 2.2 1.9 1.9 2.1 2.3 2 2 2 1.8 1.6 2.0
Median age  
at death (IQR)
27 
(13)
28
(17)
23
(14)
24
(11)
27
(20)
27
(14)
27
(18)
25
(18)
29
(15)
27
(17)
27
(18)
27 
(16)
Median LOS (IQR),  
days
7
(10)
6
(9)
7
(10)
7
(10)
7
(9)
7
(9)
7
(10)
8
(9)
7
(11)
7
(10)
7
(9)
7
(10)
Figure 1. National temporal trends of in-hospital mortality among hospitalized cystic fibrosis patients. Dark grey line represents CF patients with 
prior lung transplant. Light gray line represents all hospitalized CF patients
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Table 3.  Hospital characteristics, insurance, and discharge 
disposition of the hospitalized cystic fibrosis patients
Percentage  
distribution
Teaching status
Non Teaching 13.9
Teaching 85.2
Geographical region
Northeast 18.8
Midwest 24
South 36.5
West 18.9
Location
Rural 4.4
Urban 94.6
Hospital bed-size
Small 8.6
Medium 21.4
Large 69
Primary expected payer
Medicare 15.8
Medicaid 32.6
Private insurance 44.3
Self-pay 2
No charge 0.2
Other 4.9
Discharge disposition
Routine home discharge 73.4
Discharged with home-health care 20.9
Short/Long term care facilities 3.4
Died in hospital 1.5
All cells represent percentage distribution. Less than 2% of cases had missing 
hospital and insurance data 
Hospital bed-size categories are specific to hospital’s  location and teaching 
status [10]
Table 4.  Prevalence of chronic liver disease, acute kidney injury (AKI), and acute pancreatitis among hospitalized  
patients with cystic fibrosis between 2003 and 2013
Chronic liver disease Acute kidney injury Acute pancreatitis
Prevalence, % 3.7 3.8 1.7
Gender, %
 Male 51.3 50.4 45
 Female 48.7 49.6 55
Mean age (SD), years 22.2 (11.2) 32.1 (13.8) 28.7 (13.4)
Median LOS (IQR), days 8 (10) 11 (15) 4 (5)
Mortality % 2.5 11.2 0.8
Table 5.  Characteristics of hospitalized cystic fibrosis 
patients with a prior lung transplant 
Mean age (SD), years 30.5 (11.0)
Gender, % 
Male 46.5
Female 53.5
Prevalence of co-morbidities, %
Acute kidney injury 19.7
Chronic underlying liver disease 2.2
Complications of transplanted lung (ICD-9: 996.84) 39.9
Outcomes
In-hospital mortality, % 4.2
Median age at death (IQR), years 28 (16)
Median LOS (IQR), days 5 (6)
Total number of hospitalizations of prior lung transplant recipients was 20, 112; 
SD — standard deviation; LOS — length of stay; IQR — interquartile range
for prevalence, the annual hospitalization rates 
still trended up during this period indicating 
contribution of other factors such as the aging 
CF population [1]. This is also supported by 
our finding of increasing proportion of adults ≥ 
18 years) in the hospitalized sample over these 
years. The proportion of females hospitalized 
was consistently higher than males throughout 
the years despite a slightly higher male prepon-
derance among CF patients in the community [1]. 
This is in parallel with previous large studies 
demonstrating poorer outcomes among females 
with CF [11, 12]. 
Acute kidney injury
Prolonged or frequent courses of antibiotics 
during pulmonary exacerbation, particularly 
aminoglycosides are an important risk factor for 
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patients [13]. Pseudomonas and Staphylococcus 
aureus are the two most common respiratory 
microorganisms isolated among individuals with 
CF [1, 14]. Simultaneous utilization of multiple 
antimicrobial agents during a pulmonary exa-
cerbation is often required due to the increasing 
prevalence of multidrug resistance among these 
organisms [15, 16]. Patients with AKI were found 
to be significantly older in our study, which might 
be a risk factor for its development. Nephrotoxic 
immunosuppressive agent use in transplant reci-
pients is another factor potentially contributing 
to acute or chronic renal dysfunction [17]. Our 
study presents the novel finding that even after 
adjusting for multiple variables, the mortality of 
patients with CF who develop AKI is significantly 
higher compared to those without AKI. Conside-
ring the burden of AKI and its significant impact 
on outcomes in hospitalized CF population, 
improvement in antibiotic stewardship program 
is warranted. Other considerations would be to 
monitor the renal function of these patients even 
more closely during an exacerbation. According 
to current ‘Cystic Fibrosis Pulmonary Guidelines’ 
on treatment of pulmonary exacerbation, there 
is insufficient data on equivalence of home vs 
hospital treatment [4]. As there is only limited 
data on differences in occurrence of renal dys-
function between the treatment sites [18, 19] 
the ability to monitor renal function frequently 
should play an important role when considering 
the site of treatment for an exacerbation. In light 
of our data, another randomized controlled trial is 
needed evaluating differences in renal outcomes 
between these sites.
Patients with prior lung transplantation
Patients with prior lung transplantation con-
stituted a significant proportion (6.5%) of hospi-
talizations in our study. 90% of these were adults 
(age > 18 years). Recent literature demonstrated 
that mean age of patients with CF undergoing 
lung transplantation is increasing [20]. The same 
study by Kimura et al. [20] also reported that the 
proportion of lung transplantations performed 
for CF has decreased over time and this trend is 
particularly pronounced in pediatric population. 
In the current sample of hospitalized transplan-
ted patients, about 40% admissions were directly 
related to complications of lung transplantation. 
Further data on nature of complication could not 
be obtained due to non-specificity of ICD-9 codes 
for post transplant complications like bronchio-
litis obliterans syndrome and graft failure. Renal 
dysfunction is a common long-term complica-
tion of lung transplant [21]. Our study focuses 
only on acute kidney injury and those requiring 
dialysis in the setting of AKI. Our data suggests 
that about one in five hospitalized CF patient 
with prior lung transplantation suffers from AKI 
and every one in ten patients with AKI requires 
dialysis. This is associated with higher mortali-
ty in transplanted individuals as demonstrated 
previous studies [22]. 
Seasonal variation
There was some variation in the burden of 
admissions between meteorological seasons [23]. 
The overall number of admissions in the winter 
months was higher than summer months. Lowest 
number of admissions were recorded in May; the 
burden of admissions increased through fall to 
reach a peak in February (Fig. 2). However, as the 
study sample was nationally representative and 
distributed through 44 states, it was difficult to 
ascertain the impact of ambient temperature on 
frequency of admissions of patients with cystic 
fibrosis [6]. There is limited data in literature on 
association of seasonal variation with pulmonary 
exacerbations [24, 25].
Limitations
Several limitations of our study need to be 
acknowledged. As with any administrative da-
tabase, it was not possible to control for coding 
errors and reporting bias. The accuracy of ICD-9-
CM codes to identify cases with CF has not been 
specifically tested in NIS. Although, use of all 
ICD-9-CM codes from 277.00 to 277.09 likely in-
creased our sensitivity in identifying CF patients, 
the accuracy remains uncertain. However, the 
fair consistency of demographics and outcomes 
between our CF population and CFFPR indicates 
a well selected study population. Similarly, codes 
used for identifying AKI-D were well validated to 
use with an administrative database. Secondly, 
some factors predicting severity of pulmonary 
disease like FEV1 were not available. Lastly, as 
NIS provides each hospitalization as a separate 
entry without a unique patient identifier, it was 
not possible to identify readmissions separately. 
Despite these limitations, our study highlights 
important trends in patients hospitalized with CF 
using a large, nationally representative database.
Conclusions
In conclusion, our study demonstrates the 
recent national trends of hospitalizations of 
individuals with CF and co-morbidities in the 
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Figure 2. Distribution of admissions of patients with cystic fibrosis through calendar months. Each bar represents mean number of admission per 
day in a month
United States. Overall all-cause mortality has 
significantly decreased over this period. Median 
age at death in hospital and length of stay did 
not change significantly over the 11-year period. 
Acute kidney injury is an important co-morbidity 
with significant impact on mortality. These results 
should be helpful for developing guidelines to im-
prove quality of inpatient care, decreasing iatroge-
nic complications, providing valuable prognostic 
information, and identifying new challenges in 
the management of the increasing population of 
individuals with cystic fibrosis. 
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